Supporting Prostate Cancer Research

Prostate cancer is among the most commonly diagnosed cancers in men in Canada and continues to present major challenges. Current screening tools remain limited, the biological mechanisms driving disease progression are not fully understood, and access to targeted therapies is still restricted.

To drive progress, CRS and PROCURE launched a dedicated program to push scientific boundaries and support visionary projects with strong potential for clinical benefit. The initial plan was to fund four projects.

However, the exceptional quality and promise of proposals received led to the decision to support six projects, increasing the total investment to $3 million. All funded projects were selected through a rigorous peer-review process conducted by a committee of internationally recognized scientific experts.

Each funded project will receive $500,000 over a three-year period.

The selected projects and the researchers leading them are:

• François-Michel Boisvert – Université de Sherbrooke
  Urinary Proteomics for the Discovery of Diagnostic Biomarkers in Prostate Cancer
• Chelsia Gillis – The Research Institute of the McGill University Health Centre
  Bad Diet, Right Time: A Precision Nutrition Approach to Potentiate Radiotherapy
• Larry Goldenberg – University of British Columbia
  Rational design of a selective PSMA-targeting composite aptamer to treat lethal prostate cancer
• David Labbé – The Research Institute of the McGill University Health Centre
  Enhancing PSMA-targeted radionuclide therapy through precision nutrition and nanomedicine
• Stanley Liu – Sunnybrook Research Institute
  Harnessing multiomic immune and plasma biomarkers for oligometastatic prostate cancer
• Frédéric Pouliot – Université Laval
  4-Timepoint Multi-tracer PET imaging to characterize prOstate Cancer heterogeneity (4TMPO)

This research focuses on areas such as the identification of new biomarkers, advanced medical imaging, personalized nutrition, and the development of innovative therapies. Together, they contribute to advancing the understanding, diagnosis, and treatment of prostate cancer.

Through this significant support, CRS and PROCURE reaffirm their commitment to accelerating discoveries and transforming the future of those affected by prostate cancer.